1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Continuous Renal Replacement Therapy Market
4. Market Overview
4.1. Introduction
4.1.1. Market Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Continuous Renal Replacement Therapy Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Market Outlook
5.1. Incidence of Acute Kidney Injury Across the Globe
5.2. Rise in Prevalence of Diabetes and Hypertension
5.3. Reimbursement Scenario by Region/globally
5.4. Regulatory Scenario by Region/globally
5.5. Recent Technological Developments in Continuous Renal Replacement Therapy
5.6. Development of CRRT System for Pediatric Patients
5.7. Key Mergers & Acquisitions
6. Global Continuous Renal Replacement Therapy Market Analysis and Forecast, by Mode
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Mode, 2017–2031
6.3.1. Slow Continuous Ultrafiltration (SCUF)
6.3.2. Continuous Venovenous Hemofiltration (CVVHF)
6.3.3. Continuous Venovenous Hemodialysis (CVVHD)
6.3.4. Continuous Venovenous Hemodiafiltration (CVVHDF)
6.4. Market Attractiveness Analysis, by Mode
7. Global Continuous Renal Replacement Therapy Market Analysis and Forecast, by Product
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Product, 2017–2031
7.3.1. Dialysate & Replacement Fluids
7.3.2. Disposables
7.3.2.1. Bloodline Sets
7.3.2.2. Hemofilters
7.3.2.3. Other Disposables
7.3.3. Systems
7.4. Market Attractiveness Analysis, by Product
8. Global Continuous Renal Replacement Therapy Market Analysis and Forecast, by Therapy
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Therapy, 2017–2031
8.3.1. Renal
8.3.2. Non-renal
8.3.3. Combination
8.4. Market Attractiveness Analysis, by Therapy
9. Global Continuous Renal Replacement Therapy Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by End-user, 2017–2031
9.3.1. Hospitals
9.3.2. Clinics
9.3.3. Others
9.4. Market Attractiveness Analysis, by End-user
10. Global Continuous Renal Replacement Therapy Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Region
11. North America Continuous Renal Replacement Therapy Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Mode, 2017–2031
11.2.1. Slow Continuous Ultrafiltration (SCUF)
11.2.2. Continuous Venovenous Hemofiltration (CVVHF)
11.2.3. Continuous Venovenous Hemodialysis (CVVHD)
11.2.4. Continuous Venovenous Hemodiafiltration (CVVHDF)
11.3. Market Value Forecast, by Product, 2017–2031
11.3.1. Dialysate & Replacement Fluids
11.3.2. Disposables
11.3.2.1. Bloodline Sets
11.3.2.2. Hemofilters
11.3.2.3. Other Disposables
11.3.3. Systems
11.4. Market Value Forecast, by Therapy, 2017–2031
11.4.1. Renal
11.4.2. Non-renal
11.4.3. Combination
11.5. Market Value Forecast, by End-user, 2017–2031
11.5.1. Hospitals
11.5.2. Clinics
11.5.3. Others
11.6. Market Value Forecast, by Country, 2017–2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Mode
11.7.2. By Product
11.7.3. By Therapy
11.7.4. By End-user
11.7.5. By Country
12. Europe Continuous Renal Replacement Therapy Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Mode, 2017–2031
12.2.1. Slow Continuous Ultrafiltration (SCUF)
12.2.2. Continuous Venovenous Hemofiltration (CVVHF)
12.2.3. Continuous Venovenous Hemodialysis (CVVHD)
12.2.4. Continuous Venovenous Hemodiafiltration (CVVHDF)
12.3. Market Value Forecast, by Product, 2017–2031
12.3.1. Dialysate & Replacement Fluids
12.3.2. Disposables
12.3.2.1. Bloodline Sets
12.3.2.2. Hemofilters
12.3.2.3. Other Disposables
12.3.3. Systems
12.4. Market Value Forecast, by Therapy, 2017–2031
12.4.1. Renal
12.4.2. Non-renal
12.4.3. Combination
12.5. Market Value Forecast, by End-user, 2017–2031
12.5.1. Hospitals
12.5.2. Clinics
12.5.3. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Mode
12.7.2. By Product
12.7.3. By Therapy
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Continuous Renal Replacement Therapy Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Mode, 2017–2031
13.2.1. Slow Continuous Ultrafiltration (SCUF)
13.2.2. Continuous Venovenous Hemofiltration (CVVHF)
13.2.3. Continuous Venovenous Hemodialysis (CVVHD)
13.2.4. Continuous Venovenous Hemodiafiltration (CVVHDF)
13.3. Market Value Forecast, by Product, 2017–2031
13.3.1. Dialysate & Replacement Fluids
13.3.2. Disposables
13.3.2.1. Bloodline Sets
13.3.2.2. Hemofilters
13.3.2.3. Other Disposables
13.3.3. Systems
13.4. Market Value Forecast, by Therapy, 2017–2031
13.4.1. Renal
13.4.2. Non-renal
13.4.3. Combination
13.5. Market Value Forecast, by End-user, 2017–2031
13.5.1. Hospitals
13.5.2. Clinics
13.5.3. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Mode
13.7.2. By Product
13.7.3. By Therapy
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Continuous Renal Replacement Therapy Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Mode, 2017–2031
14.2.1. Slow Continuous Ultrafiltration (SCUF)
14.2.2. Continuous Venovenous Hemofiltration (CVVHF)
14.2.3. Continuous Venovenous Hemodialysis (CVVHD)
14.2.4. Continuous Venovenous Hemodiafiltration (CVVHDF)
14.3. Market Value Forecast, by Product, 2017–2031
14.3.1. Dialysate & Replacement Fluids
14.3.2. Disposables
14.3.2.1. Bloodline Sets
14.3.2.2. Hemofilters
14.3.2.3. Other Disposables
14.3.3. Systems
14.4. Market Value Forecast, by Therapy, 2017–2031
14.4.1. Renal
14.4.2. Non-renal
14.4.3. Combination
14.5. Market Value Forecast, by End-user, 2017–2031
14.5.1. Hospitals
14.5.2. Clinics
14.5.3. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Mode
14.7.2. By Product
14.7.3. By Therapy
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Continuous Renal Replacement Therapy Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Mode, 2017–2031
15.2.1. Slow Continuous Ultrafiltration (SCUF)
15.2.2. Continuous Venovenous Hemofiltration (CVVHF)
15.2.3. Continuous Venovenous Hemodialysis (CVVHD)
15.2.4. Continuous Venovenous Hemodiafiltration (CVVHDF)
15.3. Market Value Forecast, by Product, 2017–2031
15.3.1. Dialysate & Replacement Fluids
15.3.2. Disposables
15.3.2.1. Bloodline Sets
15.3.2.2. Hemofilters
15.3.2.3. Other Disposables
15.3.3. Systems
15.4. Market Value Forecast, by Therapy, 2017–2031
15.4.1. Renal
15.4.2. Non-renal
15.4.3. Combination
15.5. Market Value Forecast, by End-user, 2017–2031
15.5.1. Hospitals
15.5.2. Clinics
15.5.3. Others
15.6. Market Value Forecast, by Country/Sub-region, 2017–2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Mode
15.7.2. By Product
15.7.3. By Therapy
15.7.4. By End-user
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of companies)
16.2. Market Position By Company (2021)
16.3. Company Profiles
16.3.1. Baxter International, Inc.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. SWOT Analysis
16.3.1.4. Strategic Overview
16.3.2. Nipro Corporation
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. SWOT Analysis
16.3.2.4. Strategic Overview
16.3.3. Asahi Kasei Corporation
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. SWOT Analysis
16.3.3.4. Strategic Overview
16.3.4. B. Braun Melsungen AG
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. SWOT Analysis
16.3.4.4. Strategic Overview
16.3.5. Medica SPA
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. SWOT Analysis
16.3.5.4. Strategic Overview
16.3.6. INFOMED SA
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. SWOT Analysis
16.3.6.4. Strategic Overview
16.3.7. Medtronic
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. SWOT Analysis
16.3.7.4. Strategic Overview
16.3.8. Toray Medical Company Limited (Toray Industries, Inc.)
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. SWOT Analysis
16.3.8.4. Strategic Overview
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer